Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Sixth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 74 current clinical trials in our China register. 55 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Oxaliplatin, Bevacizumab and Capecitabine. The most-studied condition is Radiotherapy.

ClinicalTrials.gov trials by status

Recruiting5574%
Not yet open1216%
Active, closed45%
By invitation34%

Trials by phase

Not applicable2635%
Phase 22027%
Observational1622%
Phase 357%
Phase 434%
Phase 2/323%
Phase 111%
Phase 1/211%

Clinical trials sponsored by Sixth Affiliated Hospital, Sun Yat-sen University

74 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Prediction of Postoperative Recurrence in Crohn's Disease NCT07824791 · ClinicalTrials.gov ↗ · Crohn Disease (CD), Postoperative Recurrence and Metastasis	Observational	Recruiting	2025-07	China
Effect of Titrated Administration of Ciprofol on Perioperative Hypotension in Elderly Patients Undergoing Laparoscopic Abdominal Surgery: A Randomized Controlled Trial NCT07328958 · ClinicalTrials.gov ↗ · Hypotension During Surgery	Not applicable	Recruiting	2026-01	China
Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer NCT06719414 · ClinicalTrials.gov ↗ · Rectal Cancer	Observational	Recruiting	2024-10	China
SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC NCT07549399 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma, High-Risk Cancer, MSS Drugs: Bevacizumab, Cetuximab, MFOLFOX6	Phase 3	Recruiting	2026-05	China
A Prospective, Single-Arm Clinical Study of a Dietary Supplement for the Prevention of Acute Radiation-Induced Rectal Injury During Neoadjuvant Chemoradiotherapy for Rectal Cancer NCT07802002 · ClinicalTrials.gov ↗ · Radiotherapy, Radiation-Induced Complications	Not applicable	Recruiting	2026-07	China
Fecal Microbiota Transplantation for Radiation-Induced Proctopathy NCT06776029 · ClinicalTrials.gov ↗ · Radiation Induced Proctitis Drug: Fecal Microbiota Transplantation	Phase 2	Recruiting	2025-02	China
Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer NCT07154173 · ClinicalTrials.gov ↗ · Rectal Neoplasms, Colon Neoplasms, Microbiota	Observational	Recruiting	2025-01	China
TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response NCT07510191 · ClinicalTrials.gov ↗ · Crohn Disease (CD) Drug: Upadacitinib	Phase 4	Recruiting	2026-03	China
Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer NCT06364371 · ClinicalTrials.gov ↗ · Predictive Cancer Model, Pathologic Complete Response	Observational	Recruiting	2024-06	China
Study on Repeat Liposomal Bupivacaine for Post-Surgery Pain in Anal Fistula Patients. NCT07081373 · ClinicalTrials.gov ↗ · Anal Fistula	Not applicable	Recruiting	2025-07	China
Multicenter Prospective Observational Study of Cardiotoxicity in Patients Receiving Targeted Cancer Therapies NCT07058454 · ClinicalTrials.gov ↗ · Cancer;Cardiovascular;Adverse Events, Cancer	Observational	Recruiting	2025-09	China
Superior HypogastrIc plExus bLock During Laparoscopic Colorectal Cancer Surgery NCT07579780 · ClinicalTrials.gov ↗ · Colorectal Cancer (Diagnosis), Laparoscopic Surgery, Superior Hypogastric Plexus Block	Not applicable	Recruiting	2025-12	China
PostoperAtive Neurocognitive Dysfunction After Major AbdomiNal Surgery (PANDAMAN) NCT06182215 · ClinicalTrials.gov ↗ · Elective Major Abdominal Surgery	Observational	Recruiting	2023-12	China
Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Low Rectal Cancer NCT05943444 · ClinicalTrials.gov ↗ · Rectal Neoplasms, Low Anterior Resection Syndrome, Anastomotic Leak	Not applicable	Recruiting	2023-08	China
Stereotactic Body Radiation Therapy for Unresectable Locally Recurrent Rectal Cancer NCT07297004 · ClinicalTrials.gov ↗ · Unresectable Locally Recurrent Rectal Cancer	Phase 2	Recruiting	2025-01	China
Preoperative Oral Midazolam to Postoperative Pain Relief in Sleep Disturbance or Anxiety Patients With Colorectal Cancer NCT06407518 · ClinicalTrials.gov ↗ · Preoperative, Sleep Disturbance, Anxiety Drug: Midazolam	Not applicable	Recruiting	2024-07	China
Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety NCT07216014 · ClinicalTrials.gov ↗ · Crohn's Disease and Ulcerative Colitis	Phase 4	Recruiting	2025-12	China
Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized, Phase II Trial NCT07230639 · ClinicalTrials.gov ↗ · Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy	Phase 2	Recruiting	2025-08	China
Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy NCT03587480 · ClinicalTrials.gov ↗ · Rectal Neoplasm Malignant	Not applicable	Recruiting	2018-12	China
Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC) NCT06958419 · ClinicalTrials.gov ↗ · Immune Checkpoint Therapy, Radiotherapy, Metastatic Colorectal Cancer (CRC)	Phase 2/3	Recruiting	2025-05	China
Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease NCT06902987 · ClinicalTrials.gov ↗ · Crohn's Diseases, Active Anal Fistula, Upadacitinib Drug: Upadacitinib	Phase 1	Recruiting	2024-01	China
Predicting the Efficacy of Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Using an AI Platform Based on Multi-parametric MRI NCT05523245 · ClinicalTrials.gov ↗ · Rectal Cancer	Observational	Recruiting	2022-06	China
Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study NCT07808853 · ClinicalTrials.gov ↗ · ESCC	Phase 2	Recruiting	2026-09	China
Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer NCT04643041 · ClinicalTrials.gov ↗ · Rectal Cancer	Not applicable	Recruiting	2021-01	China
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients NCT05797467 · ClinicalTrials.gov ↗ · Colorectal Cancer, Chemotherapy Effect Drug: Bevacizumab	Phase 3	Recruiting	2023-04	China
Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis NCT03748485 · ClinicalTrials.gov ↗ · Colorectal Cancer, Adjuvant Chemotherapy	Not applicable	Recruiting	2019-04	China
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) NCT06958432 · ClinicalTrials.gov ↗ · Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy	Phase 2/3	Recruiting	2025-05	China
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease NCT07545317 · ClinicalTrials.gov ↗ · Crohn's Disease	Observational	Recruiting	2026-04	China
Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC NCT06998758 · ClinicalTrials.gov ↗ · Neoadjuvant Chemotherapy, Weight Loss Drug: Megestrol Acetate	Phase 3	Recruiting	2025-11	China
Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression NCT07176182 · ClinicalTrials.gov ↗ · Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III	Phase 2	Recruiting	2026-03	China
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) NCT07669220 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma, High-risk Locally Advanced, Short-course Radiotherapy (SCRT) Drug: Toripalimab	Phase 2	Recruiting	2026-01	China
ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer NCT05815082 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases, Circulating Tumor Cell	Phase 3	Recruiting	2023-02	China
A Retrospective Analysis of Robot-Assisted Versus Endoscopic Breast-Conserving Surgery for Breast Cancer NCT07321145 · ClinicalTrials.gov ↗ · Breast Cancer, Breast Surgery	Not applicable	Recruiting	2025-06	China
Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis NCT06095596 · ClinicalTrials.gov ↗ · Ulcerative Colitis (UC)	Not applicable	Recruiting	2023-11	China
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer NCT06510010 · ClinicalTrials.gov ↗ · Chemotherapy Effect	Phase 2	Recruiting	2024-12	China
Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease NCT07504510 · ClinicalTrials.gov ↗ · Crohn's Disease	Observational	Recruiting	2020-06	China
Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis NCT07442045 · ClinicalTrials.gov ↗ · Ulcerative Colitis (UC)	Observational	Recruiting	2023-01	China
Dietary Supplements to Treat Radiation-Induced Rectal Injury NCT06776016 · ClinicalTrials.gov ↗ · Radiotherapy, Radiation Proctitis	Phase 2	Recruiting	2025-01	China
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE） NCT06767007 · ClinicalTrials.gov ↗ · Unresectable Locally Recurrent Rectal Cancer Drug: PD1	Phase 2	Recruiting	2025-01	China
Association Between Preoperative Metformin Exposure and Postoperative Nausea and Vomiting in Patients Undergoing General Anesthesia NCT07244575 · ClinicalTrials.gov ↗ · Postoperative Nausea and Vomiting	Observational	Recruiting	2025-12	China
Predicting Gastric Cancer Response to Chemo With Multimodal AI Model NCT06451393 · ClinicalTrials.gov ↗ · Gastric Cancer, Chemotherapy Effect	Observational	Recruiting	2013-02	China
Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC NCT06002789 · ClinicalTrials.gov ↗ · Multiple Cancer, Colorectal Cancer	Phase 2	Recruiting	2022-05	China
Tubeless NOSES Versus Laparoscopic Radical Resection for Rectosigmoid Cancers NCT04037956 · ClinicalTrials.gov ↗ · Tubeless NOSES, Traditional Laparoscopic Radical Resection, Rectosigmoid Cancers	Not applicable	Recruiting	2019-06	China
Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I) NCT06923345 · ClinicalTrials.gov ↗ · Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy	Phase 2	Recruiting	2025-03	China
The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients NCT06998745 · ClinicalTrials.gov ↗ · Thrombosis, Venous	Not applicable	Recruiting	2025-05	China
Association Between Clinical Classification and Prognosis in Chronic Radiation Enteropathy NCT07378631 · ClinicalTrials.gov ↗ · Radiotherapy, Radiation Proctitis, Radiation Enteritis	Observational	Recruiting	2025-12	China
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA NCT05797077 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases, Circulating Tumor Cell Drug: Capecitabine	Phase 3	Recruiting	2023-02	China
Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma NCT06364384 · ClinicalTrials.gov ↗ · Rectal Squamous Cell Carcinoma	Phase 2	Recruiting	2024-04	China
IBD Biomarker Discovery and Validation Platform NCT07686406 · ClinicalTrials.gov ↗ · Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Diseases (IBD)	Observational	Recruiting	2022-01	China
Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial NCT07279077 · ClinicalTrials.gov ↗ · Colon Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy	Phase 2	Recruiting	2025-11	China
Proximally Extended Resection for Rectal Cancer After Neoadjuvant Chemoradiotherapy NCT02649647 · ClinicalTrials.gov ↗ · Rectal Cancer	Not applicable	Recruiting	2016-02	China
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma NCT04989985 · ClinicalTrials.gov ↗ · Locally Advanced Gastroesophageal Junction Adenocarcinoma, Chemotherapy Effect Drugs: Oxaliplatin, Sinitilimab, Tegafur Gimeracil Oteracil	Phase 2	Recruiting	2021-09	China
Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease NCT06520397 · ClinicalTrials.gov ↗ · Crohn Disease Drug: Ustekinumab	Phase 4	Recruiting	2024-07	China
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction NCT04840264 · ClinicalTrials.gov ↗ · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis Drugs: Docetaxel, Fluorouracil, Oxaliplatin	Phase 2	Recruiting	2022-01	China
Mesenteric Surgical Margin for Crohn's Disease Endoscopic Recurrence NCT06241170 · ClinicalTrials.gov ↗ · Endoscopic Recurrence Rate, After Ileocolic Crohn 's Disease Surgery	Not applicable	Recruiting	2025-07	China
Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer NCT06751394 · Recurrent Rectal Cancer Drugs: Capecitabine, Irinotecan, Oxaliplatin	Phase 2	Not yet open	2025-01	China
The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer NCT03923335 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Observational	Not yet open	2019-04	China
Inhalational Versus Intravenous Anesthesia on Postoperative Lung Injury in Septic Patients Undergoing Surgery NCT07601256 · ClinicalTrials.gov ↗ · Sepsis, Lung Injury	Not applicable	Not yet open	2026-08	China
Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC) NCT06980389 · ClinicalTrials.gov ↗ · Immune Checkpoint Therapy, Radiotherapy, Metastatic Gastric Carcinoma	Phase 2	Not yet open	2025-05	China
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer NCT06871527 · ClinicalTrials.gov ↗ · Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib Drugs: Folfox, Fruquintinib, Tislelizumab	Phase 1/2	Not yet open	2025-03	China
Preventive Efficacy of Bergmann Enema for Acute Radiation-induced Rectal Injury in Rectal Cancer Patients Undergoing Short-course Radiotherapy NCT07302126 · ClinicalTrials.gov ↗ · Acute Radiation Enteritis	Phase 2	Not yet open	2025-12	China
Effect of Different Oxygen Concentrations Before Extubation After General Anesthesia on Hypoxemia After Extubation in Post-anesthesia Care Unit NCT07293286 · ClinicalTrials.gov ↗ · Hypoxemia	Not applicable	Not yet open	2025-12	China
Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer NCT06617052 · ClinicalTrials.gov ↗ · Locally Recurrent Rectal Cancer, Preoperative Chemoradiotherapy	Observational	Not yet open	2024-09	China
Extent of Lymph Node Dissection for Advanced Right-Sided Colon Cance NCT06986538 · ClinicalTrials.gov ↗ · Advanced Right-sided Colon Cancer, the Extent of Lymph Node Dissection	Not applicable	Not yet open	2025-06	China
NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC NCT07765667 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma, High-Risk Cancer, MSS Drug: Vitamin C	Phase 2	Not yet open	2026-09	China
Improvement Effect of Dexamethasone Enema for Acute Radiation-induced Rectal Injury NCT07548736 · ClinicalTrials.gov ↗ · Acute Radiation Enteritis	Phase 2	Not yet open	2026-04	China
Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease NCT07344428 · ClinicalTrials.gov ↗ · Crohn Disease	Not applicable	Not yet open	2026-08	China
High-protein Oral Nutrition With HMB for Active CD Patients With Sarcopenia NCT07171593 · Handgrip Strength	Not applicable	By invitation	2024-03	China
Optimal Interval for Periodic Alveolar Recruitment Maneuvers Achieving 90% Lung Re-expansion During Intraoperative Ventilation NCT07239557 · ClinicalTrials.gov ↗ · Major Abdominal Surgery, Atelectasis, Lung-protective Ventilation	Not applicable	By invitation	2025-12	China
Endoscopic Balloon Dilatation Combined With PRP Injection in Colonic Stenosis in Crohn's Disease NCT06165289 · ClinicalTrials.gov ↗ · Crohn Disease	Not applicable	By invitation	2024-03	China
The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery NCT05733208 · Myocardial Injury, Non-cardiac Surgery, Remote Ischemic Preconditioning	Not applicable	Active, closed	2023-05	China
Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer NCT05953662 · ClinicalTrials.gov ↗ · Colorectal Neoplasm	Not applicable	Active, closed	2023-09	China
Clinical Study on the Effect of Umbilical Cord Mesenchymal Stem Cell Exosomes on Endometrial Repair of Intrauterine Adhesions NCT07416578 · ClinicalTrials.gov ↗ · Intrauterine Adhesions, Exosomes	Not applicable	Active, closed	2026-01	China
Reducing the Resection Range After Neoadjuvant Therapy for Locally Advanced Upper Rectal and Rectosigmoid Junction Cancers NCT07038122 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Carcinoma	Not applicable	Active, closed	2025-07	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Sixth Affiliated Hospital, Sun Yat-sen University trials

21 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Sixth Affiliated Hospital, Sun Yat-sen University trials

105 conditions

Radiotherapy8 Rectal Cancer6Immune Checkpoint Therapy6Colorectal Cancer5 Chemotherapy Effect5Neoadjuvant Therapies4Crohn Disease (CD)3Rectal Adenocarcinoma3Ulcerative Colitis (UC)3 Crohn Disease3High-Risk Cancer2MSS2Rectal Neoplasms2Unresectable Locally Recurrent Rectal Cancer2Crohn's Disease2 Liver Metastases2Circulating Tumor Cell2Acute Radiation Enteritis2Radiation Proctitis2Myocardial Injury1Non-cardiac Surgery1Remote Ischemic Preconditioning1Handgrip Strength1Recurrent Rectal Cancer1

By trial register

Register	Trials	Recruiting
Clinical trials in China	74	55

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Radiotherapy

Sponsor	Trials
Shandong Cancer Hospital and Institute	4
Hubei Cancer Hospital	2
Fujian Cancer Hospital	2
Tao Zhang	2
Chinese Academy of Medical Sciences	1
Chuangzhen Chen	1

Sponsors with the most current trials registered for this condition.

Questions about Sixth Affiliated Hospital, Sun Yat-sen University trials

How many clinical trials does Sixth Affiliated Hospital, Sun Yat-sen University sponsor?

Sixth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 74 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sixth Affiliated Hospital, Sun Yat-sen University trials recruiting?

Yes. 55 of its 74 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sixth Affiliated Hospital, Sun Yat-sen University testing?

Its current trials name 21 drugs and biologicals as interventions. The most frequent are Oxaliplatin (3), Bevacizumab (2), Capecitabine (2), Toripalimab (2) and Upadacitinib (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Sixth Affiliated Hospital, Sun Yat-sen University clinical trials